Tempus AI to Acquire Personalis for $1.5 Billion

By Hao Liu • Monday, July 20 16:00 • Permanent Link

Tempus AI has agreed to buy Personalis in a deal valuing the genomics company at $1.5 billion net of Tempus’ existing stake, with Personalis shareholders set to receive $16.25 a share.

The price implies a 6% premium to Personalis’ Friday close and a 28% premium to its unaffected 30-day volume-weighted average price.

The transaction is structured as 100% stock, though Tempus can elect to pay cash for up to 50% of the consideration. The floating exchange ratio will be finalized closer to closing, with a maximum ratio of 0.3356 Tempus shares for each Personalis share.

The companies said the deal is expected to close in late 2026 or early 2027.

Personalis reported preliminary second-quarter revenue of $22.4 million and 10,384 clinical tests, up 33% from the prior quarter. The company also said it has Medicare coverage in three indications.

Tempus said the acquisition expands its minimal residual disease capabilities and builds on a partnership launched in November 2023, when Tempus invested in Personalis and began commercializing Personalis’ next personal MRD test. Today the company's shares have moved -14.29% to a price of $13.19. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.